DGAP-News

ImevaX secures EUR 7.5 million in Series A Financing to develop highly specific vaccine against Helicobacter pylori infections - Seite 2

discussions. In the meantime, we will also apply our technology platform to
other selected infectious diseases."

"The success of the IMX 101 project is based primarily on the performance
of the whole team, the support of the Institute of Microbiology at TUM and
the confidence of our investors and the BMBF, which has contributed
significantly to the financing of ImevaX", Professor Markus Gerhard,
founder and Chief Science Officer of ImevaX GmbH said.


About ImevaX:
ImevaX is a biopharmaceutical company founded in 2014 based in Munich,
Germany. The focus is to combat chronic and nosocomial infections by
creating specific vaccines. The company's lead candidate IMX 101 is a
vaccine against Helicobacter pylori, which colonizes the stomach and is the
cause of ulcer disease and gastric cancer in humans. Founder Markus Gerhard
and his team discovered that the colonization ability (and hence, the
infectiousness) of H. pylori depends on a secreted bacterial factor that
down-regulates the host immune system. Many other highly infectious
pathogens have evolved similar immune evasion mechanisms, which are the
focus of the ImevaX screening program. For more information please visit:
www.imevax.com.

About Wellington Partners
Wellington Partners is one of the most successful pan-European venture
capital firms. With some EUR 850 million under management and offices in
London, Munich, Palo Alto and Zurich, the firm invests into companies
throughout Europe that have the potential to become global leaders in the
areas of Life Sciences, Digital Media and Software. Since 1998, Wellington
Partners has invested in more than 100 European companies, including now
publicly traded Actelion, Evolva, Genticel, Implanet, Oxford Immunotec,
Supersonic Imagine and privately held companies like AyoxxA, immatics,
invendo medical, MPM Medical, MTM Laboratories (acquired by Roche), NEUWAY
Pharma, Oxagen, Rigontec, Quanta, Sapiens (acquired by Medtronic), Sensimed
and Symetis. www.wellington-partners.com.

About BiomedPartners
BioMedPartners AG is an independent healthcare-dedicated investment firm
based in Basel, Switzerland, that provides private equity and mezzanine
financing to private early- to mid-stage healthcare and life science
companies in Switzerland and neighboring regions (Alpine Rim).
BioMedPartners have over CHF 250 million under management and have invested
in or given loans to 45 companies, including now publicly traded Affimed,
Arpida, Evolva and Santhera and the exited privately held companies Glycart
Biotechnologies (acquired by Roche), ESBATech (acquired by Alcon/Novartis),
Activaero (acquired by Vectura) and Okairos (acquired by GSK).